HAWTHORNE, N.Y.--(BUSINESS WIRE)--Nov. 13, 2008--Acorda
Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen,
M.D., President & CEO, will present at the upcoming Lazard Capital
Markets 5th Annual Healthcare Conference on Wednesday, November 19,
2008 at 9:00 a.m. ET at the St. Regis Hotel in New York, NY.
A live webcast of the presentation can be accessed under "Calendar
of Events" in the Acorda Investor Relations section of the website at
www.acorda.com, or you may use the link:
http://www.wsw.com/webcast/lz5/acor/.
Please log in approximately 5 minutes before the scheduled time of
the presentation to ensure a timely connection. An archived version of
the webcast will be available until February 19, 2009 on the Acorda
website in the Investor Relations section; to access please use the
link http://phx.corporate-ir.net/phoenix.zhtml?c=194451&p=irol-IRHome.
About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company developing
therapies for spinal cord injury, multiple sclerosis and related
nervous system disorders. The Company's marketed products include
Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug
for the management of spasticity. In June 2008, Acorda's lead clinical
product, Fampridine-SR, completed a second Phase 3 clinical trial to
evaluate its safety and efficacy in improving walking ability in
people with MS. The Company's pipeline includes a number of products
in development for the treatment, regeneration and repair of the
spinal cord and brain.
Forward-Looking Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should
be considered forward-looking. These statements are subject to risks
and uncertainties that could cause actual results to differ
materially, including delays in obtaining or failure to obtain FDA
approval of Fampridine-SR, the risk of unfavorable results from future
studies of Fampridine-SR, Acorda Therapeutics' ability to successfully
market and sell Fampridine-SR, if approved, and Zanaflex Capsules,
competition, failure to protect its intellectual property or to defend
against the intellectual property claims of others, the ability to
obtain additional financing to support Acorda Therapeutics'
operations, and unfavorable results from its preclinical programs.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda Therapeutics may not actually achieve the goals or plans
described in its forward-looking statements, and investors should not
place undue reliance on these statements. Acorda Therapeutics
disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
CONTACT: Acorda Therapeutics
Jeff Macdonald, 914-347-4300 ext. 232
jmacdonald@acorda.com
SOURCE: Acorda Therapeutics, Inc.